These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Why might micafungin be the drug of choice in pediatric patients?]. Ramos Amador JT; Prieto Tato L; Guillén Martín S Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():23-8. PubMed ID: 21420573 [TBL] [Abstract][Full Text] [Related]
4. [Micafungin in invasive candidiasis among oncohematological patients]. Jarque I; Angel Sanz M Rev Iberoam Micol; 2009 Mar; 26(1):75-7. PubMed ID: 19463282 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT. El-Cheikh J; Venton G; Crocchiolo R; Fürst S; Faucher C; Granata A; Oudin C; Coso D; Bouabdallah R; Vey N; Duran S; Fougereau E; Berger P; Chabannon C; Blaise D Bone Marrow Transplant; 2013 Nov; 48(11):1472-7. PubMed ID: 23749104 [TBL] [Abstract][Full Text] [Related]
6. Micafungin use in children. Emiroglu M Expert Rev Anti Infect Ther; 2011 Sep; 9(9):821-34. PubMed ID: 21905789 [TBL] [Abstract][Full Text] [Related]
7. [Future role of micafungin in the treatment of invasive mycoses caused by filamentous fungi]. Salavert-Lletí M; Zaragoza-Crespo R Rev Iberoam Micol; 2009 Mar; 26(1):81-9. PubMed ID: 19463284 [TBL] [Abstract][Full Text] [Related]
8. A cost and resource utilization analysis of micafungin bridging for hemato-oncological high-risk patients undergoing allogeneic stem cell transplantation. Heimann SM; Vehreschild MJ; Cornely OA; Franke B; von Bergwelt-Baildon M; Wisplinghoff H; Kron F; Scheid C; Vehreschild JJ Eur J Haematol; 2015 Jun; 94(6):526-31. PubMed ID: 25310918 [TBL] [Abstract][Full Text] [Related]
9. Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases. Cornely OA; Pappas PG; Young JA; Maddison P; Ullmann AJ Expert Opin Drug Saf; 2011 Mar; 10(2):171-83. PubMed ID: 21306282 [TBL] [Abstract][Full Text] [Related]
10. Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients. Vehreschild MJ; von Bergwelt-Baildon M; Tran L; Shimabukuro-Vornhagen A; Wisplinghoff H; Bangard C; Cornely OA; Vehreschild JJ Eur J Haematol; 2014 Nov; 93(5):400-6. PubMed ID: 24798021 [TBL] [Abstract][Full Text] [Related]
12. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections. Cross SA; Scott LJ Drugs; 2008; 68(15):2225-55. PubMed ID: 18840009 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233 [TBL] [Abstract][Full Text] [Related]
14. Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study. Nachbaur D; Angelova O; Orth-Höller D; Ditlbacher A; Lackner M; Auberger J; Lass-Flörl C Eur J Haematol; 2015 Mar; 94(3):258-64. PubMed ID: 25082655 [TBL] [Abstract][Full Text] [Related]
15. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients. Carter NJ; Keating GM Paediatr Drugs; 2009; 11(4):271-91. PubMed ID: 19566111 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of micafungin for invasive candida infections: a meta-analysis of randomized controlled trials. Chen Q; Lin MH; Chen ML; Liu ZY; Chai D; Wang R Chin Med J (Engl); 2012 Jan; 125(2):345-51. PubMed ID: 22340571 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study. Yamaguchi M; Kurokawa T; Ishiyama K; Aoki G; Ueda M; Matano S; Takami A; Yamazaki H; Sawazaki A; Yamauchi H; Yoshida T; Nakao S Ann Hematol; 2011 Oct; 90(10):1209-17. PubMed ID: 21695388 [TBL] [Abstract][Full Text] [Related]
18. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis. Ziakas PD; Kourbeti IS; Mylonakis E Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393 [TBL] [Abstract][Full Text] [Related]
20. Different doses of micafungin for prophylaxis of invasive fungal diseases in hemato-oncological high-risk patients: a web-based non-interventional trial in four large university hospitals in Germany. Heimann SM; Vehreschild MJ; Meintker L; Heinz W; Schroeder T; von Bergwelt-Baildon M; Cornely OA; Vehreschild JJ Transpl Infect Dis; 2014 Dec; 16(6):968-74. PubMed ID: 25371351 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]